345 related articles for article (PubMed ID: 12235076)
1. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Ransford RA; Langman MJ
Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
[TBL] [Abstract][Full Text] [Related]
2. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Logan RF; van Staa TP
Gut; 2003 Oct; 52(10):1530; author reply 1530-1. PubMed ID: 12970150
[No Abstract] [Full Text] [Related]
3. How safe are the safest IBD drugs?
Lewis JD
Gastroenterology; 2003 Jun; 124(7):1986-7; discussion 1987-8. PubMed ID: 12806636
[No Abstract] [Full Text] [Related]
4. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
Tebano MT; Traversa G; Da Cas R; Loizzo A
Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
[TBL] [Abstract][Full Text] [Related]
5. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
Uittenbogaart SB; Klemt-Kropp M
Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
[TBL] [Abstract][Full Text] [Related]
6. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
Corrigan G; Stevens PE
Aliment Pharmacol Ther; 2000 Jan; 14(1):1-6. PubMed ID: 10632639
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine: a global safety evaluation.
Brimblecombe R
Scand J Gastroenterol Suppl; 1990; 172():66. PubMed ID: 1972297
[TBL] [Abstract][Full Text] [Related]
8. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.
Moss JG; Parry CM; Holt RCL; McWilliam SJ
Eur J Med Res; 2022 Apr; 27(1):61. PubMed ID: 35488310
[TBL] [Abstract][Full Text] [Related]
9. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine in childhood inflammatory bowel disease.
Barden L; Lipson A; Pert P; Walker-Smith JA
Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
[TBL] [Abstract][Full Text] [Related]
11. Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.
Uslu N; Demir H; Saltik-Temizel IN; Topaloğlu R; Gürakan F; Yüce A
Dig Dis Sci; 2007 Nov; 52(11):2926-9. PubMed ID: 17404867
[TBL] [Abstract][Full Text] [Related]
12. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
Birketvedt GS; Berg KJ; Fausa O; Florholmen J
Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
[TBL] [Abstract][Full Text] [Related]
13. [Chronic interstitial nephritis and mesalazine: 3 new cases?].
Brouillard M; Gheerbrant JD; Gheysens Y; Fleury D; Devred M; Hazzan M; Colombel JF
Gastroenterol Clin Biol; 1998; 22(8-9):724-6. PubMed ID: 9823562
[TBL] [Abstract][Full Text] [Related]
14. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Brogden RN; Sorkin EM
Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine-induced interstitial nephritis.
Skalova S; Dedek P; Pozler O; Podhola M
Ren Fail; 2009; 31(2):159-61. PubMed ID: 19212915
[TBL] [Abstract][Full Text] [Related]
16. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
17. [Interstitial nephritis induced by mesalazine].
Ohya M; Otani H; Kimura K; Kodama N; Minami Y; Liang XM; Maeshima E; Yamada Y; Mune M; Yukawa S
Nihon Jinzo Gakkai Shi; 2002 May; 44(4):414-9. PubMed ID: 12073628
[TBL] [Abstract][Full Text] [Related]
18. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.
Russo L; Schneider G; Gardiner MH; Lanes S; Streck P; Rosen S
Eur J Clin Pharmacol; 2014 Jun; 70(6):709-17. PubMed ID: 24609467
[TBL] [Abstract][Full Text] [Related]
19. Acute interstitial nephritis due to mesalazine.
Tadic M; Grgurevic I; Scukanec-Spoljar M; Bozic B; Marusic S; Horvatic I; Galesic K
Nephrology (Carlton); 2005 Apr; 10(2):103-5. PubMed ID: 15877665
[TBL] [Abstract][Full Text] [Related]
20. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
Giaffer MH; O'Brien CJ; Holdsworth CD
Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
